Public Company News
Cisco Unveils Innovations Driving New Security Cloud Strategy
News Summary: * Cisco unveiled its new strategic vision of a unified platform for end-to-end security across hybrid multi-cloud environments * The company is designing the Cisco Security Cloud to be the most open security platform with no public cloud lock-in * Cisco is taking steps to real...
2022-06-06 23:00
3743
Prenetics Announces First Quarter 2022 Financial Results After a Successful Listing on the Nasdaq under the Ticker "PRE"
LONDON and HONG KONG, June 6, 2022 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced its unaudited financial results for the first quarter endedMarch 31, 2022. The Company recorded strong opera...
2022-06-06 21:55
6556
Cyient to Acquire Portugal-Based Celfinet to Strengthen its Wireless Communications Offerings
HYDERABAD, India, June 6, 2022 /PRNewswire/ -- Cyient, a leading consulting-led, industry-centric, global Technology Solutions company, today announced that it had signed definitive agreements to acquire Celfinet. An international Wireless Engineering Services company, Celfinet, is focused on pr...
2022-06-06 20:00
3020
Cuisine Solutions, Global Leader and Pioneer in Sous Vide Premium Foods, Announces $250 Million Growth Investment from Bain Capital
Investment to Accelerate Company's Growth and Global Expansion and Drive Further Culinary Innovation STERLING, Va. and BOSTON, Mass., June 6, 2022 /PRNewswire/ -- Cuisine Solutions Inc., the global leader and pioneer in sous vide premium foods, today announced a$250 million investment from Bain ...
2022-06-06 20:00
7721
Futu Holdings Achieves Solid First-Quarter Growth Amid Market Volatility with 67.9% YoY Increase in Paying Clients
- Flagship trading apps moomoo and Futubull have acquired 18.1 million global users as of quarter end PALO ALTO, Calif., June 6, 2022 /PRNewswire/ -- Moomoo's parent company Futu Holdings Limited (Nasdaq: FUTU) (Futu), a leading tech-driven online brokerage and wealth management platform, r...
2022-06-06 17:59
5565
Vection Technologies Announces Metaverse Integration for Webex Meetings at Cisco LIVE 2022
News Summary: * Vection Technologies is bringing its virtual worlds creation capabilities to Webex Meetings * Webex-first solution will be previewed at Cisco Live! in Las Vegas June 12-16 LAS VEGAS, June 6, 2022 /PRNewswire/ -- Vection Technologies is collaborating with Webex by Cisco to mak...
2022-06-06 14:18
3203
Gaotu Techedu Announces First Quarter of 2022 Unaudited Financial Results
BEIJING, June 6, 2022 /PRNewswire/ -- Gaotu Techedu Inc. (NYSE: GOTU) ("Gaotu" or the "Company"), a technology-driven education company and online large-class tutoring service provider inChina, today announced its unaudited financial results for the first quarter endedMarch 31, 2022. First Quart...
2022-06-06 14:00
5265
Market update: Strong tanker market due to sanctions and high demand for oil - Concordia Maritime
GÖTEBORG, Sweden, June 6, 2022 /PRNewswire/ -- The product tanker market has strengthened significantly during April and May, with market rates at much higher levels than for both Q1 2022 and the full year 2021. At the end of May, average spot market earnings for an MR vessel (clean) was about$36...
2022-06-06 13:39
3097
CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer
* The National Medical Products Administration approved sugemalimab for the treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy * Sugemalimab became the first anti-PD-...
2022-06-06 13:15
4532
Poster Highlighting Phase II Clinical Study of KN026 for HER2-expressing Advanced GC/GEJ Presented at 2022 ASCO
SUZHOU, China, June 6, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced that data from a phase II clinical study of KN026 (HER2 bispecific antibody) monotherapy in patients with previously treated, advance...
2022-06-06 10:49
3533
Research Updates on KN046 Presented at 2022 ASCO
SUZHOU, China, June 6, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that research updates from four clinical studies of KN046 (PD-L1/CTLA-4 bispecific antibody) presented as a poster or published online at the 2022 American Society of Clinical Oncology Annual Meeting (20...
2022-06-06 09:47
3699
SocietyOne launches transaction & savings accounts powered by Westpac
SYDNEY, June 6, 2022 /PRNewswire/ -- In its first major corporate milestone
following its acquisition by MONEYME Ltd (ASX:MME), digital finance platform
SocietyOne has launched transaction and savings accounts powered by Westpac's
Banking-as-a-Service (BaaS).
2022-06-06 09:25
4212
WuXi Biologics Launches First Commercial Drug Product Facility for Pre-Filled Syringes
* WuXi Biologics offers global partners high-efficiency and high-quality manufacturing services for clinical trial and commercial supply by increasing pre-filled syringes (PFS) capacity to 17 million units per year. * WuXi Biologics has established a global manufacturing network with 9 drug p...
2022-06-06 08:30
5061
Innovent Presents Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
SAN FRANCISCO and SUZHOU, China, June 6, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and ...
2022-06-06 08:08
4125
Innovent Presents Clinical Data of Phase I Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
SAN FRANCISCO and SUZHOU, China, June 6, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and ...
2022-06-06 08:00
4174
Innovent and IASO Bio Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
SAN FRANCISCO and SUZHOU, China, June 6, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2022-06-06 08:00
4059
Angel Yeast Increases New Energy Procurement in Green Push to Curb Carbon Emission
YICHANG, China, June 5, 2022 /PRNewswire/ -- Angel Yeast (en.angelyeast.com) (SH600298), a listed global yeast and yeast extract manufacturer, is glad to announce that the Company has been granted the green electricity certificate issued and certified by China Hubei Power Exchange Center and Chin...
2022-06-05 21:00
5768
JW Therapeutics Presents Latest Data of Carteyva® at 2022 ASCO Annual Meeting
SHANGHAI, June 5, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, presented the latest data of three clinical studies on Carteyva® (relmacabtagene autoleuce...
2022-06-05 18:30
5919
CStone presents updated results of anti-PD-1 antibody nofazinlimab in combination with lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC) at ASCO 2022
* Nofazinlimab in combination with lenvatinib as first-line treatment for unresectable hepatocellular carcinoma demonstrated an objective response rate of 45.0%. The median duration of response was not yet reached as of the data cutoff date (4.2 to 18.7+ months). The median progression free sur...
2022-06-05 08:02
6306
Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
FOSTER CITY, Calif. and SHANGHAI, June 4, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announces today that its licensing partner, Gilead Sciences, Inc. (Nasdaq: GILD), reported positive results from the primary analysis of the Phase 3 TROPiCS-02 study of Trodelvy® (sacituzumab govitecan...
2022-06-04 20:30
7611
Week's Top Stories
Most Reposted
/C O R R E C T I O N - Autodesk, Inc./
[Picked up by 1321 media titles]
2026-10-29 01:23
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1167 media titles]
2026-11-02 20:00Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software
[Picked up by 1148 media titles]
2026-10-28 20:30Piramal Pharma Limited Announces Results for Q2 and H1 FY27
[Picked up by 1084 media titles]
2026-10-28 03:28Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update
[Picked up by 1079 media titles]
2026-10-30 22:34
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
58123
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
52850
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
51202
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
20636
Lorikeet Dreamweaver enables businesses to give every customer an AI account manager
2026-11-04 22:00
15883